HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Shunsuke Endo Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tsubochi, H. Articles by Imai, T. Search for Related Content PubMed PubMed Citation Articles by Tsubochi, H. Articles by Imai, T. Related Collections Lung - cancer Related Article

Ann Thorac Surg 2006;82:1198-1204
© 2006 The Society of Thoracic Surgeons

---

Original Articles: General Thoracic

Combined Analysis of Cyclooxygenase-2 Expression With p53 and Ki-67 in Nonsmall Cell Lung Cancer

^a Department of General Thoracic Surgery, Omiya Medical Center, Jichi Medical School, Omiya, Saitama, Japan
^b Department of General Thoracic Surgery, Aomori Prefectural Central Hospital, Aomori, Japan
^c Department of Pathology, Aomori Prefectural Central Hospital, Aomori, Japan

Accepted for publication April 19, 2006.

^_* Address correspondence to Dr Tsubochi, Department of General Thoracic Surgery, Omiya Medical Center, Jichi Medical School, Amanuma-cho 1-847, Omiya, Saitama, 330-8503 Japan (Email: h-tsubochi{at}omiya.jichi.ac.jp).

BACKGROUND: Cyclooxygenase-2 (COX-2) is known to play a role in carcinogenesis and tumor progression. The aim of this study was to evaluate the relationship between COX-2 expression and clinicopathologic features, and to define the importance of COX-2 expression alone and in combination with p53 and Ki-67 expression in the clinical outcome of NSCLC.

METHODS: A total of 219 patients with stage I-IIIB nonsmall cell lung cancer (NSCLC) who previously underwent surgery were analyzed in this study. The COX-2 expression was evaluated by means of immunohistochemistry; p53 and Ki-67 immunoreactivity were also studied.

RESULTS: The COX-2 expression was observed in 137 patients (63%) and was significantly associated with lymph node metastasis and the histological grade of those with adenocarcinoma (p = 0.02 and 0.04, respectively). Kaplan-Meier analyses revealed that COX-2 expression was correlated with poor survival (p = 0.005), whereas multivariate survival analysis did not reveal COX-2 expression to be an independent prognostic factor. When the patients were stratified according to gender, age, tumor histology, and disease stage, COX-2 expression was significantly associated with unfavorable prognosis in males, younger patients ( 65 years), and those with adenocarcinoma and stage I tumors. The prognosis of patients with tumors negative for both COX-2 and p53 expression was significantly favorable, whereas those with tumors positive for COX-2 expression and with a high Ki-67 labeling index had a significantly unfavorable prognosis.

CONCLUSIONS: These findings indicate that combined immunohistochemical analysis of COX-2 with p53 and Ki-67 can be useful for identifying the prognosis of NSCLC patients.

Related Article

Invited commentary

Douglas E. Paull, Katherine Heminger, and Steven J. Berberich
Ann. Thorac. Surg. 2006 82: 1204. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				A. L. Van Dyke, M. L. Cote, G. M. Prysak, G. B. Claeys, A. S. Wenzlaff, V. C. Murphy, F. Lonardo, and A. G. Schwartz COX-2/EGFR expression and survival among women with adenocarcinoma of the lung Carcinogenesis, September 1, 2008; 29(9): 1781 - 1787. [Abstract] [Full Text] [PDF]

				D. E. Paull, K. Heminger, and S. J. Berberich Invited commentary. Ann. Thorac. Surg., October 1, 2006; 82(4): 1204 - 1204. [Full Text] [PDF]